Tom Dønnem
Professor
Job description
Head Translational Cancer Research Group, Institute of Clinical Medicine. Consultant Oncologist, Department of Oncology, University Hospital of North Norway.
Erna-Elise Paulsen,
Sigve Andersen,
Mehrdad Rakaee,
Mona Irene Pedersen,
Ana Paola Lombardi,
Mette Pøhl
et al.:
Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma
Bente Ervik,
Tom Dønnem,
May Lill Johansen
:
Dying at “home” - a qualitative study of end-of-life care in rural Northern Norway from the perspective of health care professionals
Per Niklas Benzler Waaler,
Hasse Melbye,
Henrik Schirmer,
Markus Kreutzer Johnsen,
Tom Dønnem,
Johan Fredrik Ravn
et al.:
Algorithm for predicting valvular heart disease from heart sounds in an unselected cohort
Mehrdad Rakaee,
Sigve Andersen,
K. Giannikou,
Erna-Elise Paulsen,
Thomas Karsten Kilvær,
Lill-Tove Rasmussen Busund
et al.:
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl Sholl,
Weiwei Shi,
Joao V. Alessi
et al.:
Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC
JAMA Oncology 17. November 2022 DOI
Therese Haugdahl Nøst,
Anne Heidi Skogholt,
Ilona Halva Urbarova,
Robin Mjelle,
Erna-Elise Paulsen,
Tom Dønnem
et al.:
Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer
Maria Jenvin Støen,
Sigve Andersen,
Mehrdad Rakaee,
Mona I. Pedersen,
Lise Martine Ingebriktsen,
Tom Dønnem
et al.:
Overexpression of mir-20a-5p in tumor epithelium is an independent negative prognostic indicator in prostate cancer—a multi-institutional study
Maria Jenvin Støen,
Sigve Andersen,
Mehrdad Rakaee,
Mona Irene Pedersen,
Lise Martine Ingebriktsen,
Roy M. Bremnes
et al.:
High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients
Sissel Gyrid Freim Wahl,
Yan Dai Hong,
Elisabeth Fritzke Emdal,
Thomas Berg,
Tarje Onsøien Halvorsen,
Anine Larsen Ottestad
et al.:
The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study
Mehrdad Rakaee,
Thomas Karsten Kilvær,
Simin Jamaly,
Thomas Berg,
Erna-Elise Paulsen,
Marte Berglund
et al.:
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer
British Journal of Cancer 2021 DOI
Therese H. Nøst,
Marit Holden,
Tom Dønnem,
Hege Bøvelstad,
Charlotta Rylander,
Eiliv Lund
et al.:
Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis
Thomas Karsten Kilvær,
Erna-Elise Paulsen,
Sigve Andersen,
Mehrdad Rakaee,
Roy M. Bremnes,
Lill-Tove Rasmussen Busund
et al.:
Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
Mehrdad Rakaee,
Lill-Tove Busund,
Simin Jamaly,
Erna-Elise Paulsen,
Elin Richardsen,
Sigve Andersen
et al.:
Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry
Elin Richardsen,
Sigve Andersen,
Samer Al-Saad,
Mehrdad Rakaee,
Yngve Nordby,
Mona Irene Pedersen
et al.:
Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer
Elin Richardsen,
Sigve Andersen,
Christian Melbø-Jørgensen,
Mehrdad Rakaee,
Nora Ness,
Samer Al-Saad
et al.:
MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer
Thomas Karsten Kilvær,
Mehrdad Rakaee,
Turid Hellevik,
Jørg Vik,
Luigi de Petris,
Tom Dønnem
et al.:
Differential prognostic impact of platelet-derived growth factor receptor Expression in NSCLC
Kaja Konstanse Skjefstad,
Charles Johannessen,
Thea K.W. Grindstad,
Thomas Karsten Kilvær,
Erna Elise Paulsen,
Mona Irene Pedersen
et al.:
A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer
Mehrdad Rakaee,
Thomas Karsten Kilvær,
Stig Manfred Dalen,
Elin Richardsen,
Erna Elise Paulsen,
Sigurd Hald
et al.:
Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer
Human Pathology 2018 DOI
Thomas Karsten Kilvær,
Mehrdad Rakaee,
Turid Hellevik,
Arne Östman,
Carina Strell,
Roy M. Bremnes
et al.:
Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer
Tom Dønnem,
Andrew Reynolds,
Elizabeth A. Kuczynski,
Kevin C. Gatter,
Peter B. Vermeulen,
Robert S. Kerbel
et al.:
Non-angiogenic tumours and their influence on cancer biology
Nature Reviews Cancer 2018 DOI
Thea K.W. Grindstad,
Elin Richardsen,
Sigve Andersen,
Kaja Konstanse Skjefstad,
Mehrdad Rakaee,
Tom Dønnem
et al.:
Progesterone receptors in prostate cancer: Progesterone receptor B is the isoform associated with disease progression
Sigurd Hald,
Mehrdad Rakaee,
Inigo Zubiavrre Martinez,
Elin Richardsen,
Samer Al-Saad,
Erna Elise Paulsen
et al.:
LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival
Clinical Lung Cancer 2018 DOI
Yury Kiselev,
Sigve Andersen,
Charles Johannessen,
Bjørn Fjukstad,
Karina Standahl Olsen,
Helge Stenvold
et al.:
Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer
Nora Ness,
Sigve Andersen,
Mehrdad Rakaee,
Cecilie Nordbakken,
Andrey Yurjevich Valkov,
Erna-Elise Paulsen
et al.:
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
Erna-Elise Paulsen,
Thomas Karsten Kilvær,
Mehrdad Rakaee,
Elin Richardsen,
Sigurd Hald,
Sigve Andersen
et al.:
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases
Elin Richardsen,
Sigve Andersen,
Samer Al-Saad,
Mehrdad Rakaee,
Yngve Nordby,
Mona Irene Pedersen
et al.:
Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort
Yngve Nordby,
Elin Richardsen,
Nora Ness,
Tom Dønnem,
Hitendra R.H. Patel,
Lill-Tove Busund
et al.:
High miR-205 expression in normal epithelium is associated with biochemical failure - An argument for epithelial crosstalk in prostate cancer?
Tom Dønnem,
Micklem Kingsley,
Pezzella Francesco
:
Evolution and cancer (Chapter 3), Oxford Textbook of Cancer Biology
Oxford University Press 2019
Mehrdad Rakaee,
Masoud Tafavvoghi,
Elio Adib,
Biagio Ricciuti,
Joao Alessi,
Alessio Cortellini
et al.:
Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer
2023
Bente Ervik,
Tom Dønnem,
May Lill Johansen
:
Home-death in Rural North Norway - Health Care Professionals Perspectives
2023
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl,
Weiwei Shi,
Joao V Alessi
et al.:
Computational pathology by Artificial Intelligence (AI) on quantifying the lymphocytic infiltration predicts the immunotherapy response in NSCLC
2022
Åslaug Helland,
Hege Elisabeth Giercksky Russnes,
Gro Live Fagereng,
Khalid Ibrahim Al-Shibli,
Yvonne Andersson,
Thomas Berg
et al.:
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5)
Journal of Translational Medicine 2022 DOI
Therese Haugdahl Nøst,
Ilona Halva Urbarova,
Anne Heidi Skogholt,
Robin Mjelle,
Erna Elise Paulsen,
Tom Dønnem
et al.:
Increased levels of mRNAs and miRNAs associated with imminent and advanced lung cancer
2022
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl,
Weiwei Shi,
Joao V.Alessi
et al.:
Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC
2022
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl,
Joao V.Alessi,
Alessio Cortellini
et al.:
Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer
2022
Åslaug Helland,
Hege Elisabeth Giercksky Russnes,
Gro Live Fagereng,
Khalid Ibrahim Al-Shibli,
Yvonne Andersson,
Thomas Berg
et al.:
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
Bente Ervik,
Sigve Andersen,
Helge Skirbekk,
Tom Dønnem
:
Evaluating a centralised cancer support centre in the remote region of Northern Norway
Sigve Andersen,
Tom Dønnem
:
Krafttak mot kreft
14. March 2019
Tom Dønnem
:
Lungekreftforskning i et samfunnspersepktiv
2019
Tom Dønnem,
Sigve Andersen
:
Jakter på kroppens krigerceller
05. September 2019
Tom Dønnem,
Sigve Andersen
:
Jakter på kroppens krigerceller
18. September 2019
Tom Dønnem
:
Er angiogenese en "hallmark of cancer"? - paradigmeskifte og betydning for behandling
BestPractice Nordic 2019
Tom Dønnem
:
Kræftsvulster er mere komplicerede, end forskerne tidligere antaget
19. July 2018
Tom Dønnem
:
Kreftsvulsten er mer komplisert enn forskerer tidligere har trodd
25. June 2018
Tom Dønnem
:
Knuser sentral sannhet innen kreftforskning
16. May 2018
Tom Dønnem
:
Tumours are more complicated than previously believed
04. July 2018
Kaja Konstanse Skjefstad,
Thea K.W. Grindstad,
Mehrdad Rakaee,
Elin Richardsen,
Tom Dønnem,
Thomas Karsten Kilvær
et al.:
Corrigendum to "Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer" [Steroids 113 (2016) 5-13]
Steroids 2018 DOI
Tom Dønnem
:
"Immunologi innen lungekreft"
2017
Tom Dønnem
:
"Foredrag om forskning og brukermedvirkning"
2017
Tom Dønnem
:
"IT og medisinsk forskning"
01. September 2017
The 50 latest publications is shown on this page. See all publications in Cristin here →
Research interests
Translational cancer research with emphasis on tumor immunology and angiogenesis in lung cancer. Precision medicine across many malignancies. Palliative care.